Domů › Nemalobuněčný plicní karcinom › Delaware › Newark
Klinické studie Nemalobuněčný plicní karcinom v Newark, DE
16 studií pro Nemalobuněčný plicní karcinom hledá účastníky v lokalitách v Newark a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Probíhá náborFáze 3
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Probíhá náborFáze 1/2
- Medical Oncology Hematology Consultants, Newark
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
Probíhá náborFáze 3
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Probíhá náborFáze 3
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Probíhá náborFáze 3
- Medical Oncology Hematology Consultants, PA, Newark
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Probíhá náborFáze 3
- Medical Oncology Hematology Consultants, PA, Newark
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Probíhá náborFáze 3
- Medical Oncology Hematology Consultants Helen F Graham Cancer Center, Newark
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Probíhá náborFáze 2
- ChristianaCare Helen F Graham Cancer Center and Research Institute, Newark
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Probíhá náborFáze 2
- ChristianaCare Health System, Newark
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Probíhá náborFáze 3
- Research Site, Newark
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Probíhá náborFáze 3
- Medical Oncology Hematology Consultants, PA, Newark
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Probíhá náborFáze 3
- Research Site, Newark
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Probíhá náborFáze 3
- Research Site, Newark
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Probíhá náborFáze 2/3
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Probíhá náborObservační studie
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
- Christiana Care - Union Hospital, Elkton · Vzdálenost 7 mi
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Probíhá náborObservační studie
- Massive Bio SYNERGY-AI site, Newark
Studie Nemalobuněčný plicní karcinom v jiných městech
- Houston, TX145 studií
- New York City, NY120 studií
- Arlington, VA104 studií
- Nashville, TN97 studií
- Boston, MA90 studií
- Los Angeles, CA87 studií
- St. Louis, MO73 studií
- Chicago, IL61 studií
- Baltimore, MD60 studií
- San Antonio, TX59 studií
- Columbus, OH56 studií
- Washington, DC55 studií
Další studie v Newark
- Rakovina prostaty10 studií
- Kolorektální karcinom9 studií
- Rakovina plic9 studií
- Rakovina prsu8 studií
- Metastatický karcinom7 studií
- Rakovina (všechny typy)6 studií
- Rakovina slinivky břišní6 studií
- Rakovina vaječníků5 studií
- Folikulární lymfom4 studií
- Chronická lymfocytární leukemie4 studií
- Rakovina žaludku4 studií
- Melanom4 studií
Zdroj: ClinicalTrials.gov, data načtena 5. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.